Drug details
Droxia (hydroxyurea capsules)
type of Antineoplastics, Antimetabolite
Droxia (hydroxyurea) is an antimetabolite that affects certain cells in the body, such as cancer cells or sickled red blood cells, used to treat melanoma (a type of skin cancer), chronic myelocytic leukemia, cancer of the ovary, and primary squamous cell (skin) cancer of the head and neck. Droxia is also used to treat sickle cell anemia.
This drug may have the following side effects:
- hives,
- difficulty breathing,
- swelling of your face, lips, tongue, or throat,
- nausea,
- loss of appetite,
- yellowing of the skin or eyes (jaundice)
- vomiting,
- fever,
- easy bruising,
- unusual bleeding,
- pale skin,
- lightheadedness,
- shortness of breath,
- cold hands and feet,
- chills,
- tiredness,
- wheezing,
- mouth sores,
- dark urine, and
- fast heart rate,
- dry cough,
- severe dizziness,
- numbness, tingling, or burning pain in your hands or feet,
- skin numbness or purple discoloration,
- skin ulcers,
- open sores,
- sudden chest pain,
- upper stomach pain (may spread to your back),
The following drugs are related to Droxia, either as a replacement or used together:
- BESREMi (ropeginterferon alfa-2b-njft)
- Carboplatin (carboplatin injection)
- Mycelex (clotrimazole)
- Hydrea (hydroxyurea)
- Motrin (ibuprofen)
- Imlygic (talimogene laherparepvec suspension for intralesional injection)
- Oxbryta (voxelotor tablets)
- Trental (pentoxifylline)
- Pentoxifylline Tablets (pentoxifylline)
- Rubraca Tablets (rucaparib)